Compare · BLCN vs HCXY
BLCN vs HCXY
Side-by-side comparison of Reality Shares Nasdaq NextGen Economy ETF (BLCN) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCN and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.49B.
- Over the past year, BLCN is down 0.1% and HCXY is up 0.6% - HCXY leads by 0.7 points.
- HCXY has hit the wire 3 times in the past 4 weeks while BLCN has been quiet.
Reality Shares Nasdaq NextGen Economy ETF
The investment seeks long-term growth by tracking the investment returns, before fees and expenses, of the Siren Nasdaq Blockchain Economy Index. Under normal circumstances, at least 80% of the fund's assets, will be invested in component securities of the index. The index is designed to measure the returns of companies that are committing material resources to developing, researching, supporting, innovating or utilizing blockchain technology for their proprietary use or for use by others ("Blockchain Companies"). The fund is non-diversified.
Latest BLCN
No recent items for Reality Shares Nasdaq NextGen Economy ETF.
Latest HCXY
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS